Annual report pursuant to Section 13 and 15(d)

Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements (Details Narrative)

v3.22.4
Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Apr. 08, 2022
Nov. 19, 2020
Dec. 12, 2019
Dec. 31, 2022
Dec. 31, 2021
Research and development expenses       $ 16,678 $ 14,583
Deferred revenue [1]       721 33
Revenue       3,188 33
BioNTech Agreement [Member]          
Research and development expenses $ 2,750        
Deferred revenue $ 2,750        
Revenue       3,188  
Revenue recognized       2,063  
License fee       1,125  
Accrued liabilities and other liabilities       688  
CFF Agreement [Member]          
Grants receivable       3,635  
Additional milestone payment       4,555  
CFF Agreement [Member] | Accrued Liabilities [Member]          
Other Liabilities       88 899
CFF Agreement [Member] | Cystic Fibrosis Foundation [Member]          
Therapeutics development award   $ 4,234      
Proceeds from award   484      
Additional milestone payment       321  
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]          
Research and development expenses       811 $ 2,179
Royalty payable   21,200      
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Upon Achievement Of Sales Milestones [Member]          
Royalty payable   $ 4,200      
Genentech Feasibility Study Agreement [Member] | Genentech [Member]          
Agreement description     Genentech paid the Company a total of $100 for the development of three molecules, or approximately $33 per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement    
License Agreement [Member]          
Milestone fee       100  
Annual license fee       $ 50  
[1] At December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 is related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”). Both balances are expected to be recognized by March 31, 2023. At December 31, 2021, the balance of $33 was related to the Genentech Agreement. (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other research and Development Agreements).